TW200736237A - Alkyl sulfonamide derivatives - Google Patents

Alkyl sulfonamide derivatives

Info

Publication number
TW200736237A
TW200736237A TW095118082A TW95118082A TW200736237A TW 200736237 A TW200736237 A TW 200736237A TW 095118082 A TW095118082 A TW 095118082A TW 95118082 A TW95118082 A TW 95118082A TW 200736237 A TW200736237 A TW 200736237A
Authority
TW
Taiwan
Prior art keywords
subject
compound
provides
amount
treating
Prior art date
Application number
TW095118082A
Other languages
Chinese (zh)
Inventor
Vrej Jubian
Mathivanan Packiarajan
Hermogenes Jimenez
Emily Reinhard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of TW200736237A publication Critical patent/TW200736237A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is directed to alkyl sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.
TW095118082A 2005-06-23 2006-05-22 Alkyl sulfonamide derivatives TW200736237A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15979405A 2005-06-23 2005-06-23

Publications (1)

Publication Number Publication Date
TW200736237A true TW200736237A (en) 2007-10-01

Family

ID=37595447

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095118082A TW200736237A (en) 2005-06-23 2006-05-22 Alkyl sulfonamide derivatives

Country Status (13)

Country Link
JP (1) JP2008546787A (en)
KR (1) KR20080018206A (en)
CN (1) CN101203499A (en)
AR (1) AR054480A1 (en)
AU (1) AU2006262319A1 (en)
BR (1) BRPI0612270A2 (en)
CA (1) CA2613377A1 (en)
EA (1) EA200800111A1 (en)
IL (1) IL187894A0 (en)
MX (1) MX2007015998A (en)
NO (1) NO20080411L (en)
TW (1) TW200736237A (en)
WO (1) WO2007002126A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ572381A (en) 2006-04-28 2011-01-28 Shionogi & Co Amine derivative having npy y5 receptor antagonist activity
SA08290668B1 (en) 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد Amine Derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
US8227618B2 (en) 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
MX358421B (en) * 2011-04-27 2018-08-20 Shionogi & Co 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989379B1 (en) * 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists

Also Published As

Publication number Publication date
EA200800111A1 (en) 2008-06-30
MX2007015998A (en) 2008-03-07
KR20080018206A (en) 2008-02-27
NO20080411L (en) 2008-01-22
JP2008546787A (en) 2008-12-25
CA2613377A1 (en) 2007-01-04
AU2006262319A1 (en) 2007-01-04
BRPI0612270A2 (en) 2016-09-06
WO2007002126A1 (en) 2007-01-04
CN101203499A (en) 2008-06-18
IL187894A0 (en) 2008-03-20
WO2007002126A8 (en) 2007-03-01
AR054480A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
TW200800979A (en) Halogenated sulfonamide derivatives
MY152949A (en) Novel phenylimidazole derivatives as pde10a enzyme inhibitors
UA102693C2 (en) Phenylimidazole derivatives as pde10a enzyme inhibitors
TN2012000287A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
EA200870193A1 (en) CYTOTOXIC AGENTS, INCLUDING NEW TOMAMYCIN DERIVATIVES, AND THEIR THERAPEUTIC APPLICATION
IN2015DN02829A (en)
WO2010053861A3 (en) Biologically active amides
TN2012000278A1 (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
MX2011012627A (en) Substituted aminobutyric derivatives as neprilysin inhibitors.
TN2012000271A1 (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
MX338831B (en) Selective androgen receptor modulators.
WO2009105214A3 (en) Selective androgen receptor modulators
WO2010118287A8 (en) Selective androgen receptor modulators
UA112065C2 (en) IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
MX2009003981A (en) Calcium receptor modulating agents.
NO20074047L (en) New process for the production of substituted indoles
WO2007114902A3 (en) Alkylthiobenzylpiperidine compounds
TW200736237A (en) Alkyl sulfonamide derivatives
MX2007003922A (en) Novel cyclic and acyclic propenones for treating cns disorders.
MX2012007005A (en) Bicyclic thiazoles as allosteric modulators of mglur5 receptors.
WO2007114916A3 (en) Arylbenzylpiperidine compounds
WO2006041636A3 (en) Amino substituted aryloxybenzylpiperidine derivatives
EA200601315A1 (en) 4-arylpiperidins
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers
WO2004093789A3 (en) Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods